Arax Advisory Partners’s NovoCure NVCR Stock Holding History

Arax Advisory Partners’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$404K	Buy	26,690 +7,083	+36%	+$107K	﹤0.01%	1780
2026 Q1	$214K	Sell	19,607 -2,326	-11%	-$29.1K	0.01%	1051
2025 Q4	$284K	Sell	21,933 -12,813	-37%	-$164K	0.01%	858
2025 Q3	$449K	Buy	34,746 +32,876	+1,758%	+$439K	0.01%	941
2025 Q2	$33.3K	Sell	1,870 -103	-5%	-$1.79K	﹤0.01%	1431
2025 Q1	$35.2K	Buy	1,973 +1,040	+111%	+$23.6K	﹤0.01%	1083
2024 Q4	$27.8K	Sell	933 -275	-23%	-$5.82K	﹤0.01%	1089
2024 Q3	$18.9K	Buy	1,208 +724	+150%	+$13.1K	﹤0.01%	1110
2024 Q2	$8.29K	Buy	+484	New	+$8.51K	﹤0.01%	1362

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Arax Advisory Partners's NVCR Position: Q2 2026 in Review

Arax Advisory Partners increased its NovoCure (NVCR) stake by 36% in Q2 2026, buying an estimated $107K and bringing the position to 26,690 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #1780.

Arax Advisory Partners first reported a position in NVCR in Q2 2024 and has held it in 9 quarters since. The position peaked at $449K in Q3 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Arax Advisory Partners held 26,690 shares of NovoCure worth $404K as of Q2 2026.
Arax Advisory Partners bought 7,083 NovoCure shares in Q2 2026, an estimated $107K.
NovoCure made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1780 holding.
Arax Advisory Partners first reported a position in NovoCure in Q2 2024 and has held it in 9 quarters since.
Arax Advisory Partners's NovoCure position peaked at $449K in Q3 2025.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.